Want to see AU:FRE full AI Analyst Report?

Firebrick Pharma Limited (FRE) Price & Analysis

8 Followers

FRE Stock Chart & Stats

AU$0.05

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.05

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.07

Previous CloseN/A

Volume87.61K

Average Volume (3M)73.53K

Market Cap

AU$8.33M

Enterprise ValueAU$8.14M

Total Cash (Recent Filing)AU$1.32M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta-0.16

Next Earnings

Mar 02, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding287,198,970

10 Day Avg. Volume68,142

30 Day Avg. Volume73,531

Financial Highlights & Ratios

PEG Ratio0.75

Price to Book (P/B)5.44

Price to Sales (P/S)86.36

P/FCF Ratio-3.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero-debt Balance SheetA zero-debt balance sheet limits refinancing exposure and avoids interest obligations that could further pressure a loss-making business. This provides some financial resilience and preserves flexibility to allocate capital toward product development or commercialization while leverage remains low.

Improving Cash-burn TrendThe reduction in cash burn compared with FY2023 indicates some improvement in operating cash discipline, even though the company remains cash consuming. If sustained, lower burn could extend liquidity and reduce the pace at which external funding is required.

Narrower Net LossA narrower net loss than FY2023 suggests some progress in the overall earnings trajectory, although the improvement is not yet sufficient to indicate a self-funding business. Continued execution would be needed before this becomes durable evidence of improving economics.

Bears Say

Severe Revenue ContractionA 72% revenue decline materially weakens commercial scale and indicates that recent product sales have not translated into dependable growth. Sustained contraction can reduce operating leverage, constrain investment capacity, and make future profitability harder to achieve.

Deeply Negative ProfitabilityMaterially negative gross profit means the company is not currently covering product-level costs through reported revenue, while large operating losses add further pressure. Unless margins recover, higher sales may not translate into stronger cash generation or sustainable earnings.

External Funding DependencePersistent negative operating and free cash flow means the business cannot currently fund operations internally. Dependence on external capital raises liquidity risk and may require additional equity issuance, which can dilute existing holders and restrict strategic flexibility.

Firebrick Pharma Limited News

Firebrick Pharma Sets Virtual AGM to Approve Board, Incentives and Capital Mandate

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an update. Firebrick Pharma Limited has called its Annual General...

22h ago

FRE

Firebrick Pharma Raises $732k to Accelerate Global Nasodine Expansion

Firebrick Pharma Limited ( ($AU:FRE) ) has issued an update. Firebrick Pharma has secured approximately $732,000 in strategic...

1d ago

FRE

Firebrick Pharma Sets Phased U.S. Retail Push for Nasodine After Online Sales Surge

The latest update is out from Firebrick Pharma Limited ( ($AU:FRE) ). Firebrick Pharma has unveiled a plan...

14d ago

FRE

Firebrick Pharma secures A$293,000 R&D tax incentive to support Nasodine product expansion

Firebrick Pharma Limited ( ($AU:FRE) ) has issued an announcement. Firebrick Pharma has received an A$293,000 payment under...

20d ago

FRE

Firebrick Pharma Sets Virtual AGM and Director Nomination Deadline Amid Nasodine Expansion

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an update. Firebrick Pharma Limited has scheduled its Annual General...

28d ago

FRE

Firebrick Pharma lodges ASX governance disclosures for 2026

Firebrick Pharma Limited ( ($AU:FRE) ) has provided an update. Firebrick Pharma has lodged its Appendix 4G with...

1M ago

FRE

Firebrick Pharma Revenue Slides as Loss Widens and Asset Backing Erodes

Firebrick Pharma Limited ( ($AU:FRE) ) just unveiled an announcement. Firebrick Pharma Limited reported a sharp decline in...

1M ago

FRE

Firebrick Pharma Issues Shares to Consultant in Lieu of Fees

Firebrick Pharma Limited ( ($AU:FRE) ) has issued an announcement. Firebrick Pharma Limited has issued 2,000,000 ordinary fully...

2M ago

FRE

Firebrick Pharma Seeks ASX Quotation for 2 Million New Shares

Firebrick Pharma Limited ( ($AU:FRE) ) has provided an announcement. Firebrick Pharma Limited has lodged an application with...

2M ago

FRE

Firebrick Pharma Plans Placement of Up to 2 Million New Shares

Firebrick Pharma Limited ( ($AU:FRE) ) has provided an update. Firebrick Pharma Limited has announced a proposed issue...

2M ago

FRE

FRE FAQ

What was Firebrick Pharma Limited’s price range in the past 12 months?

Firebrick Pharma Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.

What is Firebrick Pharma Limited’s market cap?

Firebrick Pharma Limited’s market cap is AU$8.33M.

When is Firebrick Pharma Limited’s upcoming earnings report date?

Firebrick Pharma Limited’s upcoming earnings report date is Mar 02, 2027 which is in 140 days.

How were Firebrick Pharma Limited’s earnings last quarter?

Firebrick Pharma Limited released its earnings results on Aug 31, 2026. The company reported -AU$0.007 earnings per share for the quarter.

Is Firebrick Pharma Limited overvalued?

According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Firebrick Pharma Limited pay dividends?

Firebrick Pharma Limited does not currently pay dividends.

What is Firebrick Pharma Limited’s EPS estimate?

Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Firebrick Pharma Limited have?

Firebrick Pharma Limited has 287,198,970 shares outstanding.

What happened to Firebrick Pharma Limited’s price movement after its last earnings report?

Firebrick Pharma Limited reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went up 6.061%.

Which hedge fund is a major shareholder of Firebrick Pharma Limited?

Currently, no hedge funds are holding shares in AU:FRE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Firebrick Pharma Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-169.20%

Trailing 12-Months

Asset Growth

18.46%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Firebrick Pharma Limited

Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.